Q1 2023 Harvard Bioscience Inc. Earnings Call

So we see this as a very strong year and continuing to develop and you've seen what the bottom line looks like now that we have so much of a better of our cost position and our overall cost organizations come down dramatically and again that you measure that in the gross margin you see that in the EBITDA margins and we are back on a nice growth path that is underpinned by these new products too so.

Thank you and as a reminder to ask a question. Please press star one one on your phone one moment. Please for our next question.

Hi, guys, just a theme for us.

We tend not to split out and report on those specifically, but.

Spansion of existing products that includes both volume and price.

But maybe and I'm, maybe interpreting it wrong maybe.

Don't discount American Americas. The U S is also growing very nicely and we see that continuing so we don't really see it's just that when all three are performing well, it's hard to differentiate because when you've got one of them that's really outperforming the rest.

In like mid term like in the next couple of years.

How do you see.

Customers the mix up and customized changing like.

Okay, well. Thank you for joining us. This ends today's presentations, we hope you'll join us in the summer for our second quarter results for fiscal 2023. Thank you and this ends the presentation.

Okay.

[music].

Okay.

[music].

Okay.

Yes.

[music].

Hum.

[music].